Specialty
Chronic respiratory diseases are a leading cause of death, disability and reduced quality of life for millions of people around the world. Novartis is committed to addressing unmet needs in this therapeutic area by developing practical and innovative solutions that provide new approaches to treatment for patients and physicians.
- Xolair (omalizumab) for patients with severe allergic asthma
- TOBI (tobramycin inhalation solution) and TOBI Podhaler (tobramycin inhalation powder) for Pseudomonas aeruginosa lung infection in patients with cystic fibrosis.
To learn more about our commitment to the treatment of another serious respiratory condition, chronic obstructive pulmonary disease (COPD), visit our page on Primary Care – Respiratory.
